1. Search Result
Search Result
Results for "

6a

" in MedChemExpress (MCE) Product Catalog:

233

Inhibitors & Agonists

15

Biochemical Assay Reagents

8

Peptides

6

Inhibitory Antibodies

11

Natural
Products

35

Recombinant Proteins

5

Isotope-Labeled Compounds

58

Antibodies

2

Click Chemistry

89

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-127103
    FB23-2
    Maximum Cited Publications
    26 Publications Verification

    Apoptosis Cancer
    FB23-2 is a potent and selective inhibitor of mRNA N 6-methyladenosine (m 6A) demethylase FTO, with an IC50 of 2.6 μM. FB23-2 has anti-proliferation activity. FB23-2 can be used for the research of acute myeloid leukemia (AML) .
    FB23-2
  • HY-W037893
    CHMA1004 dihydrochloride
    2 Publications Verification

    Methyl piperazine-2-carboxylate dihydrochloride; METTL3 activator-1

    METTL3 HIV Infection Neurological Disease
    CHMA1004 (Methyl piperazine-2-carboxylate; METTL3 activator-1) dihydrochloride is a METTL3/METTL14/WTAP methyltransferase complex activator. CHMA1004 dihydrochloride exhibits neuroprotective and anxiolytic potential by enhancing m 6A methylation modification of RNA. CHMA1004 dihydrochloride promotes HIV replication in an infection context. CHMA1004 dihydrochloride can be used in studies related to anxiety disorders and HIV-1 infection .
    CHMA1004 dihydrochloride
  • HY-158409

    Molecular Glues Ras Cyclophilin PERK Cancer
    Pan-rasin-2 (compound 6A) is an orally active molecular glues that targets RAS. Pan-RAS-IN-2 inhibits pERK (IC50 in AsPC-1 cells: 0.3 nM). Pan-rasin-2 has significant inhibitory activity on cell proliferation of RAS mutant cell lines. Pan-rasin-2 can form ternary complexes with cyclophilin A (CYPA) and RAS (ON) proteins and the formation of ternary complexes can block the binding of RAF downstream of RAS, which has anti-tumor (such as colorectal cancer, pancreatic cancer) effects .
    Pan-RAS-IN-2
  • HY-13036A

    Btk Cancer
    IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct . Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM .
    IBT6A
  • HY-13997
    Ombitasvir
    5+ Cited Publications

    ABT-267

    HCV Infection
    Ombitasvir is a potent inhibitor of the hepatitis C virus protein NS5A, with EC50s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a.
    Ombitasvir
  • HY-155489
    DDO-2728
    2 Publications Verification

    Anaplastic lymphoma kinase (ALK) Apoptosis Cancer
    DDO-2728 (compound 19) is a selective AlkB homologue 5 (ALKBH5) inhibitor with an IC50 of 2.97 μM. DDO-2728 increases the abundance of N 6 methyladenosine (m 6A) modifications, inducing cell apoptosis and cycle arrest. DDO-2728 suppresses tumor growth in the MV4 11 xenograft model with favorable safety profile, shows the potential of targeting ALKBH5 in cancer research .
    DDO-2728
  • HY-160415
    WD6305
    2 Publications Verification

    PROTACs Apoptosis METTL3 Cancer
    WD6305 is a potent and selective METTL3-METTL14 PROTAC degrader. WD6305 has DC50 values of 140 nM and 194 nM for METTL3 and METTL14, respectively. WD6305 inhibits m 6A modification and proliferation of AML cells, and induces apoptosis. WD6305 has antitumor activity .(Pink: UZH2 (HY-115717); Black: Linker; Blue: VHL ligand (HY-150803))
    WD6305
  • HY-101532

    β-CDN3; 6a-deoxy-6a-azido-β-cyclodextrin

    Biochemical Assay Reagents Others
    6A-Azido-6A-deoxy-β-cyclodextrin (β-CDN3) is a site-specifically modified β-cyclodextrin with a single azido group replacing the hydroxyl group at the C6 position. 6A-Azido-6A-deoxy-β-cyclodextrin forms a host-guest inclusion complex with Dexamethasone (HY-14648), localizing the drug within its hydrophobic cavity, which restricts the rotational mobility of the drug and places Dexamethasone in a less polar environment. 6A-Azido-6A-deoxy-β-cyclodextrin acts as a coupling agent to graft β-cyclodextrin onto thermosensitive nanogels via strain-promoted alkyne-azide cycloaddition (SPAAC). 6A-Azido-6A-deoxy-β-cyclodextrin also serves as a click chemistry reagent. It contains an azide group and undergoes copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules bearing an alkyne group. It also undergoes strain-driven alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups .
    6A-Azido-6A-deoxy-β-cyclodextrin
  • HY-176848

    YTHDF Apoptosis MMP Caspase Cancer
    SKLB-Y13 is a selective YTHDF1 inhibitor with an IC50 of 0.76 μM and a KD of 5.097 μM. SKLB-Y13 binds to the Tyr397 and Trp470 residues in the m 6A-binding pocket of YTHDF1, disrupting the interaction between YTHDF1 and m 6A-modified mRNA. SKLB-Y13 inhibits cancer cell proliferation and promotes apoptosis. SKLB-Y13 is applicable to breast cancer-related research .
    SKLB-Y13
  • HY-174982

    YTHDF Cancer
    YTHDF2 ligand-1 (Compound 23) is a competitive, selective, and high-affinity YTHDF2 ligand with an IC50 of 11 μM and a Kd of 1.3 μM. YTHDF2 ligand-1 competes with m 6A-RNA for binding to YTHDF2. YTHDF2 ligand-1 is applicable for cancer research .
    YTHDF2 ligand-1
  • HY-165422

    Anaplastic lymphoma kinase (ALK) Cancer
    ALKBH5-IN-3 is a selective, cell active ALKBH5 inhibitor with an IC50 of 0.021 μM. ALKBH5-IN-3 stabilizes ALKBH5 in HepG2 cells, and increases m 6A level in intact cells. ALKBH5-IN-3 can be used as a versatile chemical probe to explore the biological function of ALKBH5. ALKBH5-IN-3 can be used for the research of Cancer .
    ALKBH5-IN-3
  • HY-160415A
    WD6305 TFA
    2 Publications Verification

    PROTACs Apoptosis METTL3 Cancer
    WD6305 TFA is a potent and selective METTL3-METTL14 PROTAC degrader. WD6305 TFA has DC50 values of 140 nM and 194 nM for METTL3 and METTL14, respectively. WD6305 TFA inhibits m 6A modification and proliferation of AML cells, and induces apoptosis. WD6305 TFA has antitumor activity .(Pink: UZH2 (HY-115717); Black: Linker; Blue: VHL ligand (HY-150803))
    WD6305 TFA
  • HY-100014
    KDM5A-IN-1
    4 Publications Verification

    Histone Demethylase Cancer
    KDM5A-IN-1 is a potent, orally bioavailable pan-histone lysine demethylases 5 (KDM5) inhibitor with IC50s of 45 nM, 56 nM and 55 nM for KDM5A, KDM5B and KDM5C, respectively, and with an EC50 value of 960 nM for PC9 H3K4Me3. KDM5A-IN-1 is significantly less potent against other KDM5B enzymes (1A, 2B, 3B, 4C, 6A, 7B) .
    KDM5A-IN-1
  • HY-153469

    ADC Payload Cancer
    Benzyl DC-81 (Compound 6a) is an anticancer agent with antiproliferative activity against A375 and MCF-7 cells .
    Benzyl DC-81
  • HY-P10387
    RSM3
    1 Publications Verification

    METTL3 Apoptosis MDM-2/p53 NF-κB Caspase Cancer
    RSM3 is a METTL3-METTL14 complex inhibitor with a Kd of 3.10 μM for the METTL3-METTL14 complex. RSM3 reduces the m 6A modification level of SLC31A1 and the global RNA methylation level. RSM3 upregulates programmed cell death-related genes, enhances cell apoptosis, inhibits pro-cancer signals and suppresses tumor growth. RSM3 is applicable to the research of preeclampsia and cancer .
    RSM3
  • HY-172158
    ALKBH5-IN-5
    1 Publications Verification

    Anaplastic lymphoma kinase (ALK) Caspase Cancer
    ALKBH5-IN-5 is a highly selective ALKBH5 (IC50 = 0.62 μM, Kd = 804 nM). ALKBH5-IN-5 disrupts ALKBH5 binding to m 6A-RNA and 6mA-DNA substrates. ALKBH5-IN-5 promotes differentiation, induces apoptosis, cause G2-M phase arrest and exerts strong antiproliferative effects in cancer cells. ALKBH5-IN-5 reduces TACC3 and MYC protein levels and increases cleaved caspase-3 levels. ALKBH5-IN-5 exerts antitumor activity in tumor xenograft mice models. ALKBH5-IN-5 can be used for the research of acute myeloid leukemia .
    ALKBH5-IN-5
  • HY-173008

    Apoptosis YTHDF Cancer
    YTHDF2-IN-1 (Compound CK-75) is a selective YTHDF2 inhibitor (Kd = 26.2 μM). YTHDF2-IN-1 binds to a small hydrophobic pocket on the YTH domain of YTHDF2, disrupting the interaction between YTHDF2 and m 6A-modified RNA. YTHDF2-IN-1 induces cell cycle arrest and Apoptosis. YTHDF2-IN-1 is applicable to research on chronic myeloid leukemia, colon cancer and choriocarcinoma .
    YTHDF2-IN-1
  • HY-168878

    METTL3 Cancer
    EP652 is a METTL3 inhibitor and antitumor agent with IC50 values of 2 nM, <10 nM, and 37 nM in SPA, intracellular, and ATPlite assays, respectively. EP652 exhibits high selectivity against 40 other methyltransferases and FTO, and possesses favorable pharmacokinetic parameters. EP652 reduces intracellular N 6-methyladenosine (m 6A) levels in mRNA. EP652 inhibits tumor growth and progression of both hematologic malignancies and solid tumors. EP652 can be used for the research of acute myeloid leukemia, ovarian cancer, non-small cell lung cancer, and hypopharyngeal squamous cell carcinoma .
    EP652
  • HY-149145

    Anaplastic lymphoma kinase (ALK) Fat Mass and Obesity-associated Protein (FTO) Cancer
    Ena15 is an ALKBH5 inhibitor. Ena15 enhances the demethylase activity of FTO. Ena15 increases m 6A RNA level, and stabilizes FOXM1 mRNA. Ena15 suppresses the growth activity of glioblastoma multiforme .
    Ena15
  • HY-W017441A

    Phosphorylase Cancer
    hUP1-IN-1 potassium (compound 6a) is a hUP1 inhibitor with Kii and Kis Urd of 375 and 635 nM. hUP1-IN-1 potassium showes inhibitory activities over hUP1 catalyzed reaction with 70% at 1 μM. hUP1-IN-1 potassium can be used for the research of cancer .
    hUP1-IN-1 potassium
  • HY-147696

    HSP AMPK Reactive Oxygen Species (ROS) Cancer
    SMTIN-T140 (compound 6a) is a potent TRAP1 (tumor-necrosis-factor-receptor associated protein 1) inhibitor, with an IC50 of 1.646 μM. SMTIN-T140 shows anticancer activity. SMTIN-T140 leads to mitochondrial dysfunction, increases mitochondrial ROS production and activates AMPK. SMTIN-T140 potently suppressed tumor growth without any noticeable in vivo toxicity in a mouse model xenografted with PC3 prostate cancer cells .
    SMTIN-T140
  • HY-P10387A
    RSM3 TFA
    1 Publications Verification

    METTL3 Apoptosis Cancer
    RSM3 TFA is a METTL3-METTL14 complex inhibitor with a Kd of 3.10 μM for the METTL3-METTL14 complex. RSM3 TFA reduces the m 6A modification level of SLC31A1 and the global RNA methylation level. RSM3 TFA upregulates programmed cell death-related genes, enhances cell apoptosis, inhibits pro-cancer signals and suppresses tumor growth. RSM3 TFA is applicable to the research of preeclampsia and cancer .
    RSM3 TFA
  • HY-13036

    Btk Cancer
    (Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct . Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM .
    (Rac)-IBT6A
  • HY-W653776

    Drug Intermediate Others
    (6a,11β)-11,20-Dihydroxy-6-methyl-3-oxopregna-1,4,17(20)-trien-21-al is a Methylprednisolon (HY-B0260) impurity.
    (6a,11β)-11,20-Dihydroxy-6-methyl-3-oxopregna-1,4,17(20)-trien-21-al
  • HY-144377

    RAR/RXR Neurological Disease Metabolic Disease Cancer
    RXR antagonist 1 (compound 6a) is a retinoid X receptor (RXR) modulator. RXR antagonist 1 shows potent RXR-antagonistic activity, with a pA2 of 8.06. RXR antagonist 1 can be used for type 2 diabetes research .
    RXR antagonist 1
  • HY-170668

    Anaplastic lymphoma kinase (ALK) Fat Mass and Obesity-associated Protein (FTO) Cancer
    DDO-02267 is a selective and lysine-targeting covalent inhibitor of ALKBH5, with an IC50 value of 0.49 μM. DDO-02267 increases N 6-methyladenosine (m 6A) levels and targets the ALKBH5-AXL signaling axis. DDO-02267 can serve as a probe for investigating the biological function of mRNA demethylase .
    DDO-02267
  • HY-179267

    Fat Mass and Obesity-associated Protein (FTO) c-Myc RAR/RXR Apoptosis Cancer
    FTO-IN-16 (Compound 8a-1), a FTO-IN-15 (HY-179266) prodrug, is a potent FTO inhibitor. FTO-IN-16 suppresses acute myeloid leukemia (AML) cell viability, increases m 6A levels, downregulates c-Myc and CEBPA, and upregulates ASB2 and RARA. FTO-IN-16 induces apoptosis. FTO-IN-16 demonstrates strong in vivo efficacy in AML mouse xenografts. FTO-IN-16 can be used for the research of AML .
    FTO-IN-16
  • HY-W741297

    Isotope-Labeled Compounds Others
    6a-Hydroxy Testosterone-d3 is the deuterium labeled 6a-Hydroxy Testosterone.
    6a-Hydroxy Testosterone-d3
  • HY-N16604

    Drug Derivative Others
    (+)-3β-Hydroxycarvotagenone (Compound (4S,5R)-(−)-6a) is a α-phellandrene (HY-121615) derivative .
    (+)-3β-Hydroxycarvotagenone
  • HY-161022

    ADC Linker Cancer
    FL118-C3-O-C-amide-C-NH2 (compound 6a) is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
    FL118-C3-O-C-amide-C-NH2
  • HY-168874

    TrxR Apoptosis Ferroptosis Cancer
    TrxR1-IN-2 (Compound 6a) is a TrxR1 inhibitor that covalently binds to the Cys475 and Sec498 sites of TrxR1, thereby inhibiting TrxR1 activity and leading to redox homeostasis disruption, which triggers apoptosis and ferroptosis .
    TrxR1-IN-2
  • HY-163379

    Complement System Inflammation/Immunology
    C5aR1 antagonist 2 (Compound 6a) is an orally active C5a receptor 1 (C5aR1) antagonist that shows efficacy in inhibiting the C5a-induced neutrophil count increase. C5aR1 antagonist 2 is potent in the DISCO and migration assays, with IC50 values of 21 and 3 nM, respectively. C5aR1 antagonist 2 can be used for the research of acute and chronic inflammatory diseases .
    C5aR1 antagonist 2
  • HY-146679

    HDAC Amyloid-β Cholinesterase (ChE) Neurological Disease
    HDAC6-IN-6 (compound 6a) is a potent and BBB-penetrated HDAC6 inhibitor, with an IC50 of 0.025 μM. HDAC6-IN-6 exhibits strong inhibitory activity against 1-42 self-aggregation and AChE, with IC50 values of 3.0 and 0.72 μM. HDAC6-IN-6 can enhance neurite outgrowth without significant neurotoxicity .
    HDAC6-IN-6
  • HY-W125425

    Methyl piperazine-2-carboxylate; METTL3 activator-1 free base

    METTL3 HIV Infection Neurological Disease
    CHMA1004 (Methyl piperazine-2-carboxylate; METTL3 activator-1 free base) is a METTL3/METTL14/WTAP methyltransferase complex activator . CHMA1004 exhibits neuroprotective and anxiolytic potential by enhancing m 6A methylation modification of RNA. CHMA1004 promotes HIV replication in an infection context. CHMA1004 can be used in studies related to anxiety disorders and HIV-1 infection .
    CHMA1004
  • HY-170959

    Ferroptosis Neurological Disease Metabolic Disease
    NYY-6a is a Ferroptosis inhibitor. NYY-6a shows significant inhibitory activity against RSL3-induced ferroptosis across 786-O and HT-1080 cells with EC50s of 52 and 50 nM, respectively. NYY-6a functions as a radical trapping antioxidant (RTA) with efficacy of diminishing lipid peroxidation comparable to ferrostatin-1 and liproxtatin-1. NYY-6a is potential for ferroptosis related pathologies reasearch .
    NYY-6a
  • HY-N3712

    6a,12a-Dehydrodeguelin

    Others Others
    Dehydrodeguelin (6a,12a-Dehydrodeguelin) is a nature product that could be isolated from the leaves of Amorpha fruticosa L .
    Dehydrodeguelin
  • HY-N3718

    Others Others
    6a,12a-Dehydro-α-toxicarol is a natural product that can be isolated from Amorpha fruticosa .
    6a,12a-Dehydro-α-toxicarol
  • HY-134561

    6a-8tFP

    Prion Protein Infection
    6-Amino-8-trifluoromethylphenanthridine (6A-8tFP) is an antiprion agent and a derivative of 6-aminophenanthridine (HY-135189). It inhibits protein folding activity of the ribosome (PFAR) when used at a concentration of 150 μM.2 6A-8tFP directly competes with protein substrates for the ribosomal active site.
    6-Amino-8-trifluoromethylphenanthridine
  • HY-W719959

    Biochemical Assay Reagents Metabolic Disease
    3a,6a-Dihydroxy-7-oxo-5b-cholan-24-oic acid is an ester product.
    3a,6a-Dihydroxy-7-oxo-5b-cholan-24-oic acid
  • HY-N9058

    Others Others
    6-Formyl-1,2,9,10-tetramethoxy-6a,7-dehydroaporphine is a Alkaloids product that can be isolated from the aerial parts of Aconitum carmichaelii. .
    6-Formyl-1,2,9,10-tetramethoxy-6a,7-dehydroaporphine
  • HY-13036B

    Btk Cancer
    IBT6A hydrochloride is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct . Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM .
    IBT6A hydrochloride
  • HY-P1184

    Reactive Oxygen Species (ROS) Cardiovascular Disease Neurological Disease Metabolic Disease
    HNGF6A is a humanin analogue. HNGF6A increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A inhibits of ROS production during oxidative stress. HNGF6A can prevent endothelial dysfunction and atherosclerosis in vivo .
    HNGF6A
  • HY-162029

    Tyrosinase Cancer
    Tyrosinase-IN-20 (compound 6a) is a potent inhibitor of Tyrosinase with an IC50 of 28.50 μM .
    Tyrosinase-IN-20
  • HY-139563

    Drug Intermediate Others
    Lenalidomide-C10-OH (6a) is an intermediate in the synthesis of INY-03-041 .
    Lenalidomide-C10-OH
  • HY-Z2775R

    Reference Standards
    (6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a,10-trimethyl-6a,6b,7,8,8a,8b,11a,12,12a,12b-decahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4(2H)-one (Budesonide Impurity) (Standard) is the analytical standard of (6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a,10-trimethyl-6a,6b,7,8,8a,8b,11a,12,12a,12b-decahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4(2H)-one (Budesonide Impurity). This product is intended for research and analytical applications.
    (6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a,10-trimethyl-6a,6b,7,8,8a,8b,11a,12,12a,12b-decahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4(2H)-one (Budesonide Impurity) (Standard)
  • HY-170766

    PIN1 Others
    PIN1 inhibitor 4 (compound 6a) is a covalent inhibitor of peptidyl-prolyl isomerase Pin1, with IC50=3.15 μM .
    PIN1 inhibitor 4
  • HY-128934

    Others Inflammation/Immunology Cancer
    Antitumor agent-2 is sourced from patent CN102250203, compound 6a-r, has antitumor action and anti-inflammatory action .
    Antitumor agent-2
  • HY-168852

    Bacterial Infection
    Antimicrobial agent-37 (compound 6a) is a potent broad-spectrum antimicrobial agent that has a biofilm-destroying effect, acting on bacterial membranes and cracking them .
    Antimicrobial agent-37
  • HY-W424792A

    Carbonic Anhydrase Drug Metabolite Neurological Disease
    O-Desmethyl Brinzolamide hydrochloride (compound 6a), an active metabolite of Brinzolamide, is a carbonic anhydrase (CA) inhibitor with a Kd of 0.136 nM for CA II and an IC50 of 165 nM for CA IV .
    O-Desmethyl Brinzolamide hydrochloride
  • HY-163567

    RSV Infection
    RSV-IN-10 (compound 6a) shows antiviral activity against RSV with the IC50 of 4 μM. RSV-IN-10 can be used for study of respiratory infection .
    RSV-IN-10

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: